Duquesne Family Office LLC Grows Position in SpringWorks Therapeutics, Inc. (NASDAQ:SWTX)

Duquesne Family Office LLC grew its position in shares of SpringWorks Therapeutics, Inc. (NASDAQ:SWTX - Free Report) by 21.9% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 859,694 shares of the company's stock after purchasing an additional 154,628 shares during the quarter. Duquesne Family Office LLC owned approximately 1.16% of SpringWorks Therapeutics worth $31,061,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Huntington National Bank lifted its stake in shares of SpringWorks Therapeutics by 38.2% in the fourth quarter. Huntington National Bank now owns 694 shares of the company's stock worth $25,000 after acquiring an additional 192 shares during the period. AlphaQuest LLC increased its holdings in shares of SpringWorks Therapeutics by 70.2% during the fourth quarter. AlphaQuest LLC now owns 1,004 shares of the company's stock valued at $36,000 after acquiring an additional 414 shares in the last quarter. Venturi Wealth Management LLC bought a new stake in shares of SpringWorks Therapeutics during the fourth quarter valued at approximately $45,000. KBC Group NV increased its holdings in shares of SpringWorks Therapeutics by 59.1% during the fourth quarter. KBC Group NV now owns 2,634 shares of the company's stock valued at $95,000 after acquiring an additional 978 shares in the last quarter. Finally, US Bancorp DE grew its holdings in SpringWorks Therapeutics by 56.0% during the fourth quarter. US Bancorp DE now owns 4,336 shares of the company's stock worth $157,000 after buying an additional 1,556 shares in the last quarter.

Insider Buying and Selling

In other SpringWorks Therapeutics news, COO Badreddin Edris sold 20,000 shares of the stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $54.23, for a total transaction of $1,084,600.00. Following the transaction, the chief operating officer now directly owns 169,712 shares in the company, valued at $9,203,481.76. This represents a 10.54% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Saqib Islam sold 29,328 shares of the stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $60.30, for a total transaction of $1,768,478.40. Following the transaction, the chief executive officer now owns 1,034,625 shares in the company, valued at approximately $62,387,887.50. The trade was a 2.76% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 158,016 shares of company stock worth $9,102,946. Insiders own 7.83% of the company's stock.

SpringWorks Therapeutics Stock Performance

Shares of SpringWorks Therapeutics stock traded down $0.15 during trading on Monday, hitting $46.12. The company's stock had a trading volume of 4,784,455 shares, compared to its average volume of 2,009,177. The company has a market capitalization of $3.46 billion, a PE ratio of -13.25 and a beta of 0.77. SpringWorks Therapeutics, Inc. has a 52 week low of $28.21 and a 52 week high of $62.00. The company has a fifty day simple moving average of $44.35 and a two-hundred day simple moving average of $41.76.

SpringWorks Therapeutics (NASDAQ:SWTX - Get Free Report) last announced its quarterly earnings results on Friday, May 9th. The company reported ($1.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.81) by ($0.30). SpringWorks Therapeutics had a negative net margin of 134.73% and a negative return on equity of 46.74%. The company had revenue of $49.09 million for the quarter, compared to analysts' expectations of $64.19 million. As a group, analysts predict that SpringWorks Therapeutics, Inc. will post -2.05 EPS for the current year.

Wall Street Analyst Weigh In

Several equities research analysts have recently issued reports on SWTX shares. Wedbush reaffirmed a "neutral" rating and set a $47.00 target price (down from $81.00) on shares of SpringWorks Therapeutics in a research report on Monday, April 28th. Evercore ISI cut shares of SpringWorks Therapeutics from a "strong-buy" rating to a "hold" rating in a research note on Monday, April 28th. HC Wainwright restated a "neutral" rating and issued a $47.00 price objective (down from $74.00) on shares of SpringWorks Therapeutics in a report on Wednesday, April 30th. Barclays restated an "equal weight" rating and issued a $47.00 price objective (down from $63.00) on shares of SpringWorks Therapeutics in a report on Monday, April 28th. Finally, Cowen lowered shares of SpringWorks Therapeutics to a "hold" rating in a report on Tuesday, April 29th. Seven equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the company's stock. According to data from MarketBeat.com, SpringWorks Therapeutics presently has a consensus rating of "Hold" and an average price target of $52.57.

SpringWorks Therapeutics Profile

SpringWorks Therapeutics, Inc, a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for underserved patient populations suffering from rare diseases and cancer. Its lead product candidate is OGSIVEO (nirogacestat), an oral small molecule gamma secretase inhibitor that is in Phase III DeFi trial for the treatment of desmoid tumors; and Nirogacestat, is also in Phase 2 clinical development as a monotherapy for the treatment of ovarian granulosa cell tumors (GCT), a subtype of ovarian cancer.